Elizabeth Warren

Of course, the interim deal does not give us everything that we want. That is the nature of a negotiation. Each side has to give a little.

We should not be loading our students down with debt that they are going to be obligated to deal with for a lifetime when they did not get an education in return for that.

If accreditors are doing the main thing we need them to do, which is to crackdown on poor performing schools, that there is a problem here.

We have got to give the information to our students and to the Federal Government so that we are not pouring more resources into a place that is not providing a top quality education.

Should there be a bright-line beyond which we say a school should not be accredited?

It is essential to ensure that our taxpayer dollars are going to schools that are good stewards of this investment.

It is not only whether or not finance serves to help support the manufacturing we need, but whether or not finance has actually helped destroy much of the manufacturing we need.

There are reserve requirements that could be lessened for lending to the SME community.

We are not aiming for the Chinese jobs. We are aiming for the German jobs that help us build a strong and robust middle class.

This company was one of the great American companies, and it was emasculated by unfair China trade, pure and simple.

How do we get these larger financial institutions to start lending to smaller manufacturers again here in the United States?

If we only do so, then we are going to be leaving millions of American women and men behind.

So it can be done in six months if it involves safety.

So you are telling me that this is going to be a real priority for the FDA and that you are going to get this rule through.

So when does the FDA plan to use its regulatory authority to implement effective, standardized patient information for prescription drugs?

Are you saying you have some doubt about whether or not giving patients information that is effective, about how they should take their medications, is within the scope of the authority of the FDA?

I really am asking a when question. What is your timeline for when we are going to get these identifications, this information, into the hands of consumers?

If the FDA cannot commit to get this done in a reasonable time, then it is time for Congress to act.

So, Dr. Woodcock, I actually--remember, I actually worked at one of these regulatory agencies and got this process started.

I want to apologize for being late. We are doing flood insurance on the floor and have a Banking hearing going on simultaneously.

Yes, they do say that. For a reason.

I think this is a really central question when it comes to housing finance. Who is going to take on the credit risk of all these mortgages?

So you are saying there needs to be more regulation.

I do not think the Government should be standing behind structured transactions if those transactions do not work in a TBA market.

So we need some kind of regulatory structure around this.